RegeneMed

About:

RegeneMed develops drugs by providing integrated, high-throughput platforms incorporating engineered human tissue-based assays.

Website: http://www.regenemed.com

Top Investors: Tech Coast Angels

Description:

RegeneMed accelerates the development of safer, more effective drugs by providing integrated high throughput platforms incorporating engineered human tissue-based assays. Their patented, proprietary, core technologies enable in vitro growth of engineered human tissues, including liver, GI tract, bone marrow, blood-brain barrier, cardiovascular and neuronal. The first and critical application of these tissue-based in vitro model systems is to replace cell-based assays and animal testing to debottleneck ADME/Tox evaluation, the leading cause of drug failures facing the pharmaceutical industry.

Total Funding Amount:

$1M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

San Diego, California, United States

Founded Date:

2003-01-01

Contact Email:

info(AT)regenemed.com

Founders:

Number of Employees:

11-50

Last Funding Date:

2007-01-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai